Stiripentol
Approved · EMAAlso known as Diacomit, Estiripentol, 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol, 4,4-Dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol+1 more
Diacomit, Estiripentol, 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol, 4,4-Dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol, Stiripentolum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic… Show full indicationShow less
Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.